Becton, Dickinson and Company Stock: Analyst Estimates & Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Company Overview and Performance: Becton, Dickinson and Company (BDX), a global medical technology firm, has seen its shares drop 27.4% over the past year, underperforming the S&P 500 and the SPDR S&P Health Care Equipment ETF. Despite a revenue increase in Q2 2025, mixed results led to an 18.1% decline in share price following earnings release.
Future Outlook and Analyst Ratings: BDX raised its fiscal 2025 revenue outlook but lowered adjusted EPS guidance, affecting investor confidence. Analysts maintain a "Moderate Buy" consensus rating, with a revised price target of $196, while the highest target suggests a potential upside of 65.4%.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 206.040
Low
183.00
Averages
202.38
High
220.00
Current: 206.040
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
